In a patient with an elevated hematocrit (~57%) and hemoglobin 16.9 g/dL, what management steps should be taken while awaiting JAK2 mutation testing?

Immediate Management: Start Phlebotomy Now

You should immediately begin therapeutic phlebotomy to bring the hematocrit below 45%, and start low-dose aspirin (81 mg daily) unless contraindicated—do not wait for JAK2 results. 1

Why Act Now

Your patient's hematocrit of 57% places them at significantly elevated thrombotic risk. The landmark CYTO-PV trial demonstrated that maintaining hematocrit <45% versus 45-50% reduced cardiovascular death and major thrombotic events dramatically (2.7% vs 9.8%, HR 3.91). This benefit exists regardless of the underlying cause of erythrocytosis. 1

Phlebotomy Protocol

Induction phase:

• Remove 300-450 mL of blood weekly or twice weekly
• Continue until hematocrit reaches <45%
• With hematocrit at 57%, expect to need multiple sessions over 2-4 weeks

Monitoring:

• Check hematocrit after each phlebotomy initially
• Once target achieved, monitor every 1-2 weeks initially, then adjust frequency based on stability 1

Aspirin Therapy

Start aspirin 81 mg daily now, unless:

• Platelet count >1500 × 10⁹/L (extreme thrombocytosis increases bleeding risk and contraindicates aspirin) 2
• History of significant bleeding
• Known aspirin allergy or intolerance

The ECLAP trial demonstrated aspirin significantly reduces cardiovascular death, myocardial infarction, stroke, and venous thromboembolism in polycythemia vera. 2

Risk Stratification While Waiting

Assess whether your patient is high-risk, which would trigger cytoreductive therapy consideration once diagnosis is confirmed:

High-risk criteria:

• Age >60 years
• Prior thrombotic event (stroke, MI, DVT, PE, splanchnic vein thrombosis)

If high-risk, prepare to add hydroxyurea or interferon-alpha once JAK2 results confirm polycythemia vera. 1

Additional Immediate Steps

Check these labs now if not already done:

• Complete blood count with differential (look for leukocytosis >15 × 10⁹/L or thrombocytosis >1500 × 10⁹/L)
• Serum erythropoietin level (will be low-normal or suppressed in PV, elevated in secondary causes)
• Basic metabolic panel
• Oxygen saturation

Clinical assessment:

• Screen for symptoms: pruritus (especially after warm shower), erythromelalgia, visual disturbances, headache
• Examine for splenomegaly (present in ~36% of PV patients) 3
• Document cardiovascular risk factors and manage aggressively (smoking cessation, blood pressure control, lipid management) 1

Critical Pitfall to Avoid

Do not delay phlebotomy waiting for genetic testing. The thrombotic risk from hematocrit 57% is immediate and substantial. Whether this proves to be polycythemia vera, secondary erythrocytosis, or another cause, the hematocrit must be lowered urgently. The CYTO-PV trial's findings apply to the physiologic consequences of elevated hematocrit regardless of etiology. 1

What Happens When JAK2 Results Return

If JAK2 V617F positive (>95% of PV cases):

• Confirms polycythemia vera diagnosis
• Continue phlebotomy maintenance
• Continue aspirin
• Add cytoreductive therapy (hydroxyurea or interferon-alpha) if high-risk 1

If JAK2 V617F negative:

• Order JAK2 exon 12 mutation testing (present in 2-3% of PV)
• Investigate secondary causes: sleep apnea, COPD, renal disease, erythropoietin-secreting tumors, testosterone use, SGLT2 inhibitors 4, 3
• Consider hereditary erythrocytosis if longstanding and family history present 4

The key principle: treat the hematocrit elevation now to prevent thrombosis, refine the diagnosis later.